Mobile

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Mise à jour : Il y a 4 ans
Référence : NCT01347190

Femme et Homme

Extrait

Study to assess safety and tolerability of a single dose of study-drug administered to Cystic Fibrosis (CF) patients.

Critère d'inclusion

  • Cystic fibrosis

Liens